News & Updates

Show Multimedia Only

Two chemo cycles sufficient prior to HSCT in MRD-negative acute myeloid leukaemia

For children and young adults with acute myeloid leukaemia (AML) and measurable residual disease (MRD) negativity, proceeding to allogeneic hematopoietic stem cell transplant (HSCT) after two rounds of chemotherapy is as effective as completing a third cycle prior to HSCT, yielding similar transplant outcomes, according to a multicentre retrospective study.

Two chemo cycles sufficient prior to HSCT in MRD-negative acute myeloid leukaemia

7 hours ago

Intravitreal anti–VEGF injections tied to cataract development, surgery

8 hours ago

Long-term treatment with intravitreal antivascular endothelial growth factor (anti-VEGF) appears to elevate the risk of developing cataract that requires surgical intervention, reports a study.

Intravitreal anti–VEGF injections tied to cataract development, surgery

8 hours ago

Rucaparib prolongs time to subsequent therapy in advanced ovarian cancer

9 hours ago by

In patients with newly diagnosed advanced ovarian cancer, treatment with rucaparib delays the median time to first and second subsequent anticancer therapy for almost 1 year relative to placebo, according to a study presented at ESMO Gyn 2026.

Rucaparib prolongs time to subsequent therapy in advanced ovarian cancer

9 hours ago

Dostarlimab plus chemo prolongs survival in advanced dMMR/MSI-H endometrial cancer

10 hours ago by

Treatment with dostarlimab combined with carboplatin and paclitaxel (CP) confers sustained long-term progression-free survival (PFS) and overall survival (OS) benefits on patients with primary advanced or recurrent deficient mismatch repair and microsatellite instability-high (dMMR/MSI-H) endometrial cancer, as shown by the results of the phase III RUBY trial.

Dostarlimab plus chemo prolongs survival in advanced dMMR/MSI-H endometrial cancer

10 hours ago

Study shows long-term benefit of proximal HNS in OSA

11 hours ago by

Proximal hypoglossal nerve stimulation (pHGNS) delivers durable improvements in patients with obstructive sleep apnoea (OSA) in the phase III THN*3 trial.

Study shows long-term benefit of proximal HNS in OSA

11 hours ago

Wearables, smartphones promote physical activity among CVD patients

15 hours ago

Among patients with cardiovascular disease (CVD), the use of smartphones and wearable devices leads to substantial gains in daily steps and minutes spent in moderate-to-vigorous physical activity, according to a systematic review and meta-analysis.

Wearables, smartphones promote physical activity among CVD patients

15 hours ago

Adjunctive GLP-1 RA treatment of limited benefit in stable IBD patients with obesity, diabetes

a day ago

In patients with stable inflammatory bowel disease (IBD) receiving advanced therapies who have comorbid obesity and/or diabetes, adjunctive treatment with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide or tirzepatide does not appear to improve clinical outcomes, according to new research.

Adjunctive GLP-1 RA treatment of limited benefit in stable IBD patients with obesity, diabetes

a day ago

Chemo-free regimen a potential new standard of care in paediatric APL

a day ago by

In children with newly diagnosed acute promyelocytic leukaemia (APL), the use of a chemotherapy-free treatment protocol is safe and efficacious, according to the early final results of the ICC-APL-02 study.

Chemo-free regimen a potential new standard of care in paediatric APL

a day ago

Anti-interleukin-5 monoclonal antibody for asthma passes phase 1 trial

a day ago

A novel long-acting anti-interleukin-5 monoclonal antibody, SHR-1703, demonstrates promising efficacy with good tolerability in patients with eosinophilic asthma, according to a phase 1 study.

Anti-interleukin-5 monoclonal antibody for asthma passes phase 1 trial

a day ago

Novel factor B inhibitor superior to eculizumab in paroxysmal nocturnal haemoglobinuria

a day ago by

Treatment with the factor B inhibitor HSK39297 is more efficacious than eculizumab for the management of paroxysmal nocturnal haemoglobinuria (PNH), with no serious safety concerns, suggests a study presented at EHA 2026.

Novel factor B inhibitor superior to eculizumab in paroxysmal nocturnal haemoglobinuria

a day ago

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Two chemo cycles sufficient prior to HSCT in MRD-negative acute myeloid leukaemia

Two chemo cycles sufficient prior to HSCT in MRD-negative acute myeloid leukaemia

Intravitreal anti–VEGF injections tied to cataract development, surgery

Intravitreal anti–VEGF injections tied to cataract development, surgery

Rucaparib prolongs time to subsequent therapy in advanced ovarian cancer

Rucaparib prolongs time to subsequent therapy in advanced ovarian cancer

Dostarlimab plus chemo prolongs survival in advanced dMMR/MSI-H endometrial cancer

Dostarlimab plus chemo prolongs survival in advanced dMMR/MSI-H endometrial cancer

Study shows long-term benefit of proximal HNS in OSA

Study shows long-term benefit of proximal HNS in OSA

Wearables, smartphones promote physical activity among CVD patients

Wearables, smartphones promote physical activity among CVD patients

Adjunctive GLP-1 RA treatment of limited benefit in stable IBD patients with obesity, diabetes

Adjunctive GLP-1 RA treatment of limited benefit in stable IBD patients with obesity, diabetes

Chemo-free regimen a potential new standard of care in paediatric APL

Chemo-free regimen a potential new standard of care in paediatric APL

Anti-interleukin-5 monoclonal antibody for asthma passes phase 1 trial

Anti-interleukin-5 monoclonal antibody for asthma passes phase 1 trial

Novel factor B inhibitor superior to eculizumab in paroxysmal nocturnal haemoglobinuria

Novel factor B inhibitor superior to eculizumab in paroxysmal nocturnal haemoglobinuria